Navigation Links
IRIDEX Announces FDA 510(k) and CE Clearance of New Laser Delivery System for Fast, Non-invasive Treatment of Serious Retinal Diseases
Date:12/3/2012

MOUNTAIN VIEW, Calif., Dec. 3, 2012 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced the FDA 510(k) and CE clearance of the TxCell Scanning Laser Delivery System.  The new product saves significant time in a variety of laser photocoagulation procedures in allowing physicians to deliver the laser in a multi-spot scanning mode, a more efficient method for these procedures than the traditional single spot mode.  

"Broadening market acceptance for medical technologies typically involves effective clinical results, ease of use for the physicians and more efficient use of time.  TxCell can deliver all three benefits and is an important step in accelerating the adoption of our proprietary MicroPulse technology as it applies to several clinical procedures," stated Will Moore, IRIDEX President and CEO. 

Giovanni Staurenghi, MD, Professor of Ophthalmology and Chairman of the Eye Clinic Ospedale Sacco at the University of Milan was the first to use the new system.  Prof. Staurenghi stated, "TxCell Scanning Laser Delivery System with the IQ 577 offers an intuitive and versatile way to deliver several advanced laser modalities."

The TxCell Scanning Laser Delivery System combined with an IRIDEX IQ 532 or IQ 577 laser enabled with MicroPulse is designed to provide the ophthalmologist a highly versatile system with three laser modalities – multi-spot scanning, single spot standard, and MicroPulse Laser Therapy. Initial shipments have commenced with orders from a number of different countries.

About MicroPulse Technology
MicroPulse is a Fovea-friendly tissue-sparing laser delivery therapy that works by electronically "chopping" the laser emission into trains of microsecond pulses. This enhances the physician's ability to more precisely control the laser effects on target tissues, offering the potential for ocular treatment with less collateral effects than conventional laser treatments. 

About IRIDEX
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.

Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the effectiveness and market acceptance of the TxCell Scanning Laser Delivery System and MicroPulse laser therapy, and IRIDEX' marketing and sales efforts.  These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors.  Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011, and our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2012, June 30, 2012, and September 29, 2012, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.


'/>"/>
SOURCE IRIDEX Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. QUANTEL Medical Signs Global Licensing Agreement with IRIDEX
2. IRIDEX Announces Tender Offer to Purchase up to 487,500 Shares of its Common Stock
3. IRIDEX Reports 2012 Third Quarter Results
4. IRIDEX Announces Third Quarter 2012 Conference Call and Release Date
5. IRIDEX Appoints Chairman William M. Moore as Interim President & CEO
6. IRIDEX Reports 2012 Second Quarter Results
7. IRIDEX Announces Second Quarter 2012 Conference Call and Release Date
8. IRIDEX Reports 2012 First Quarter Results
9. IRIDEX Introduces Non-Invasive MicroPulse™ Therapy for Glaucoma
10. Hill-Rom Announces First Quarter 2013 Dividend
11. PDL BioPharma Announces Resignation of Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Oct. 12, 2017 West Pharmaceutical Services, ... solutions for injectable drug administration, today announced that it ... opens on Thursday, October 26, 2017, and will follow ... business expectations at 9:00 a.m. Eastern Time. To participate ... (International). The conference ID is 94093362. ...
(Date:10/10/2017)... 10, 2017  NDS received FDA 510(k) clearance in May 2017 ... display stand specifically designed for endoscopy environments. An innovative secondary monitor ... clinical solution to support the improvement of patient outcomes, procedural efficiency, ... ... ...
(Date:10/4/2017)... , Oct. 4, 2017  According to the Centers for Disease Control ... of October . PhysicianOne Urgent Care is helping communities across ... NY , by offering no-cost* flu shots through the end of ... by certain health insurance regulations. ... best time to get a flu shot is by the end of ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
Breaking Medicine News(10 mins):